Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
Saved in:
| Title: | Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. |
|---|---|
| Authors: | Roboz GJ; Weill Cornell Medicine and the New York Presbyterian Hospital, New York, NY, USA., Larson ML; Rush University Medical Center, Chicago, IL, USA., Rubenstein SE; Franciscan Health, Indianapolis, IN, USA., Solomon SR; The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA, USA., Schiller GJ; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., An Q; Jazz Pharmaceuticals, Palo Alto, CA, USA., Chiarella M; Jazz Pharmaceuticals, Palo Alto, CA, USA., Louie AC; Jazz Pharmaceuticals, Palo Alto, CA, USA., Lin TL; University of Kansas Medical Center, Kansas City, KS, USA. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2020 May; Vol. 61 (5), pp. 1188-1194. Date of Electronic Publication: 2020 Feb 26. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1029-2403 |
|---|---|
| DOI: | 10.1080/10428194.2020.1725503 |
